Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience
Radiotherapy and Oncology, ISSN: 0167-8140, Vol: 99, Issue: 2, Page: 120-123
2011
- 70Citations
- 54Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations70
- Citation Indexes69
- 69
- CrossRef54
- Clinical Citations1
- PubMed Guidelines1
- Captures54
- Readers54
- 54
Article Description
Hilar cholangiocarcinoma (Klatskin tumor–KT) accounts for about 0.5–1.5% of all gastrointestinal cancers and for 40–60% of all biliary malignancies. Tumor resection is attainable in about 30–50% of patients. When resection is not possible other treatment options have little or no impact on survival. We present the results of hypofractionated Stereotactic Body Radiotherapy (SBRT) on a small series of non resectable locally advanced KT patients.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0167814011002088; http://dx.doi.org/10.1016/j.radonc.2011.05.016; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=80955180566&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/21621289; https://linkinghub.elsevier.com/retrieve/pii/S0167814011002088
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know